Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine plus fludarabine and 2 Gy TBI conditioning before allogeneic HCT for poor-risk AML in first remission
NL-OMON40360Phase 2Active, not recruiting
- Sponsor
- Radboud University Medical Center
- Start
- Oct 2014
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of decitabine and fludarabine in acute myeloid leukemia (AML), sponsored by Radboud University Medical Center. Primary endpoints: Relapse at 1 year after transplantation, Treatment-related mortality at 1 year after transplantation and 2 more. Started Oct 2014; status: active, not recruiting.
02
Drugs
decitabinefludarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NL-OMON40360.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON40360.